Drugs - Supprelin LA [Endo Pharmaceuticals]; Lupron Depo-Ped [Abbott]
Both Supprelin LA and Lupron Depo-Ped are indicated only for central precocious puberty (CPP), which is a relatively rare disorder, with an incidence rate of about 1:5,000 – 1:10,000 individuals in the general population. It is more frequent in girls than in boys.
Criteria for use
Definitive diagnosis of central precocious puberty (CPP) as identified below.
Exclusion criteria for use
- Girls age >11 years
- Boys age >12 years
Diagnoses of central precocious puberty (CPP)
Onset of secondary sexual characteristics earlier than 8 years in females and 9 years in males
Clinical diagnosis should be confirmed by the following:
- Confirmation of diagnosis by a pubertal response to a GnRH stimulation test
- Bone age advanced one year beyond the chronological age
Baseline evaluation should also include:
- Height and weight measurements
- Sex steroid levels
Once the diagnoses of CPP is made, patients may continue on this medication until they reach the exclusion age (girls age = 11 years, boys age = 12 years).
MHCP Provider Call Center 651-431-2700 or 800-366-5411